Bacillus calmette-guerin substrain connaught live antigen

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates
Name
Bacillus calmette-guerin substrain connaught live antigen
Accession Number
DB10804
Type
Biotech
Groups
Approved, Investigational
Biologic Classification
Vaccines
Attenuated
Description

Bacillus calmette-guerin substrain connaught live antigen is intravesically administered for the treatment and prophylaxis of carcinoma in situ (CIS) of the urinary bladder and for the prophylaxis of primary or recurrent stage Ta and/or T1 papillary tumors following transurethral resection (TUR). The solution contains live, attenuated strain of Mycobacterium bovis. It is prepared from the Connaught strain of Bacillus Calmette and Guérin.

Synonyms
  • BCG, Live, Connaught Strain
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Unlock Additional Data
Bcg Vaccine (freeze-dried)Powder, for solutionIntradermalSanofi Pasteur Limited1961-12-312015-08-18Canada
ImmucystPowder, for suspensionIntravesicalSanofi Pasteur Limited1990-12-312018-01-31Canada
TheracysInjection, powder, lyophilized, for solution81 mg/3mLIntravesicalSanofi Pasteur Limited2011-07-222017-05-08Us
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Categories
UNII
5H5854UBMZ
CAS number
Not Available

Pharmacology

Indication

Indicated for intravesical use in the treatment and prophylaxis of carcinoma in situ (CIS) of the urinary bladder and for the prophylaxis of primary or recurrent stage Ta and/or T1 papillary tumors following transurethral resection (TUR).

Associated Conditions
Associated Therapies
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Unlock Additional Data
2-MethoxyethanolThe risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with 2-Methoxyethanol.
9-(N-methyl-L-isoleucine)-cyclosporin AThe risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
AbacavirThe therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Abacavir.
AbataceptThe risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Abatacept.
AbetimusThe risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Abetimus.
ActeosideThe risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Acteoside.
AcyclovirThe therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Acyclovir.
AdafosbuvirThe therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Adafosbuvir.
AdalimumabThe risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Adalimumab.
AdefovirThe therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Adefovir.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Substance
347910910
RxNav
76469
AHFS Codes
  • 80:12.00 — Vaccines

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedTreatmentCancer, Bladder1
3Not Yet RecruitingTreatmentCancer, Bladder1
3RecruitingTreatmentCancer, Bladder1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Powder, for solutionIntradermal
Powder, for suspensionIntravesical
Injection, powder, lyophilized, for solutionIntravesical81 mg/3mL
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Classification
Not classified

Drug created on December 01, 2015 13:04 / Updated on February 27, 2020 21:29